Mechanisms and Extent of Enhanced Passive Permeation by Colloidal Drug Particles
Authors:
Open Access
- 23 August 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (9) , 3085-3099
Abstract
Formulations containing nanosized drug particles such as nanocrystals and nanosized amorphous drug aggregates recently came into light as promising strategies to improve the bioavailability of poorly soluble drugs. However, the increased solubility due to the reduction in particle size cannot adequately explain the enhanced bioavailability. In this study, the mechanisms and extent of enhanced passive permeation by drug particles were investigated using atazanavir, lopinavir, and clotrimazole as model drugs. Franz diffusion cells with lipid-infused membranes were utilized to evaluate transmembrane flux. The impact of stirring rate, receiver buffer condition, and particle size was investigated, and mass transport analyses were conducted to calculate transmembrane flux. Flux enhancement by particles was found to be dependent on particle size as well as the partitioning behavior of the drug between the receiver solution and the membrane, which is determined by both the drug and buffer used. A flux plateau was observed at high particle concentrations above amorphous solubility, confirming that mass transfer of amorphous drug particles from the aqueous solution to the membrane occurs only through the molecularly dissolved drug. Mass transport models were used to calculate flux enhancement by particles for various drugs at different conditions. Good agreements were obtained between experimental and predicted values. These results should contribute to improved bioavailability prediction of nanosized drug particles and better design of formulations containing colloidal drug particles.Keywords
Funding Information
- University of Connecticut
This publication has 70 references indexed in Scilit:
- The Solubility–Permeability Interplay When Using Cosolvents for Solubilization: Revising the Way We Use Solubility-Enabling FormulationsMolecular Pharmaceutics, 2012
- Precipitation of a Poorly Soluble Model Drug during In Vitro Lipolysis: Characterization and Dissolution of the PrecipitateJournal of Pharmaceutical Sciences, 2010
- The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation DevelopmentJournal of Pharmaceutical Sciences, 2010
- Aqueous Boundary Layers Related to Oral Absorption of a Drug: From Dissolution of a Drug to Carrier Mediated Transport and Intestinal Wall MetabolismMolecular Pharmaceutics, 2010
- Salt formation to improve drug solubilityAdvanced Drug Delivery Reviews, 2007
- Cyclodextrins and their pharmaceutical applicationsInternational Journal of Pharmaceutics, 2007
- Use of a Biophysical-Kinetic Model to Understand the Roles of Protein Binding and Membrane Partitioning on Passive Diffusion of Highly Lipophilic Molecules Across Cellular BarriersJournal of Drug Targeting, 1993
- Theoretical and Experimental Studies of Transport of Micelle-Solubilized SolutesJournal of Pharmaceutical Sciences, 1982
- An Analysis of Unstirred Layers in Series with "Tight" and "Porous" Lipid Bilayer MembranesJournal of General Physiology, 1971
- Contributions of unstirred-layer effects to apparent electrokinetic phenomena in the gall-bladderThe Journal of Membrane Biology, 1969